1. Introduction {#sec1-ijms-21-02548}
===============

Deubiquitinases (DUBs) deconjugate ubiquitin (UBQ) from ubiquitylated substrates to regulate their activities and stability. They are a heterogeneous group of cysteine proteases and metalloproteases \[[@B1-ijms-21-02548]\] that cleave the isopeptide bond between a lysine and the C-terminus of UBQ. DUBs can also edit UBQ chains and process UBQ precursors. In addition, some DUBs can edit UBQ-like proteins and their conjugates. DUBs in the human genome can be classified into subclasses based on their UBQ-protease domains \[[@B1-ijms-21-02548]\]: UBQ-specific proteases (USPs), which represent the largest class, otubain proteases (OTUs), UBQ C-terminal hydrolases (UCHs), Machado--Joseph disease proteases (MJDs), Jab1/Mov34/Mpr1 Pad1 N-terminal+ (MPN+) (JAMM) motif proteases, and motif interacting with ubiquitin-containing novel DUB family (MINDY) \[[@B2-ijms-21-02548]\]. In addition, some new potential DUBs without the above typical domains were currently identified, such as the monocyte chemotactic protein-induced protein (MCPIP) \[[@B3-ijms-21-02548]\] and Zn-finger and UFSP domain protein (ZUFSP) \[[@B4-ijms-21-02548]\]. Approximately 100 DUBs have been identified in humans. They are expressed and located in various organelles in the cell \[[@B5-ijms-21-02548]\]: USP1 and USP7 are found in the nucleus, USP30 in the mitochondria, and USP21 and USP33 in microtubules. More examples are shown in [Table 1](#ijms-21-02548-t001){ref-type="table"} \[[@B5-ijms-21-02548],[@B6-ijms-21-02548],[@B7-ijms-21-02548],[@B8-ijms-21-02548]\]. Some DUBs have higher expressions in specific tissues, such as USP3 and UCHL3 in the pancreas and lung and USP14 in the brain \[[@B5-ijms-21-02548]\].

There has been extensive research on ubiquitination \[[@B9-ijms-21-02548],[@B10-ijms-21-02548]\] and how DUBs regulate the deubiquitylation process and their relative functions \[[@B11-ijms-21-02548]\]. Moreover, an increasing number of studies have uncovered the role of DUBs in cancer development \[[@B12-ijms-21-02548]\]. Numerous informative reviews on DUBs have been published \[[@B13-ijms-21-02548],[@B14-ijms-21-02548],[@B15-ijms-21-02548],[@B16-ijms-21-02548],[@B17-ijms-21-02548],[@B18-ijms-21-02548]\] and research on DUBs has been increasing in recent years. In this review, we aim to provide enriched content that summarizes the classical discoveries, and includes the current findings on DUBs that are related to different aspects of human cancer, including proliferation, cell cycle control, apoptosis, the DNA damage response (DDR), tumor suppression, oncogenesis, and metastasis. Summarized information is shown in [Table 2](#ijms-21-02548-t002){ref-type="table"}. Lastly, we discuss the potential of DUBs as chemotherapeutic targets for cancer treatment.

2. DUBs and Cell Cycle Control {#sec2-ijms-21-02548}
==============================

The cell cycle refers to a series of processes, including DNA synthesis, S phase; cell growth, G1 phase; evaluation of the accuracy of the genomic material, G2 phase; and cell division, M phase. The cycle is completed by duplicating the genetic information and equally segregating it into two daughter cells. Many cell cycle checkpoints are controlled by cyclins and cyclin-dependent kinases (CDKs) \[[@B19-ijms-21-02548]\]. The E3 ligases participate at almost every phase, indicating the importance of ubiquitination and deubiquitination in regulating the cell cycle \[[@B20-ijms-21-02548],[@B21-ijms-21-02548]\].

The ability to advance through different stages of the cell cycle regardless of inhibitory signals is one of the hallmarks of cancer. A large number of DUBs have been found to play roles in cell cycle control of cancers via the regulation of different cell cycle checkpoints. OTUD6B-2 and USP17 were reported to control the G1 phase; USP3, USP10, USP14, USP17, USP20, and BAP1 played roles in the G1/S transition. In addition, S/G2 transition was controlled by OTUD7B and DUB3. USP7 and OTUD7B were necessary for the regulation of mitotic phase ([Figure 1](#ijms-21-02548-f001){ref-type="fig"}).

For the G1 phase regulation, OTUD6B operates downstream of mTORC1 signaling in non-small cell lung cancer (NSCLC), and its isoform OTUD6B-2, was reported to control the stability of cyclin D1 and c-Myc \[[@B24-ijms-21-02548]\]. USP17 is another cell cycle-regulating DUB. It was found to be highly expressed in colon, esophageal, and cervical cancers. The depletion of USP17 increases the levels of the CDK inhibitor p21 and impairs the G1-S transition, leading to cell cycle arrest \[[@B31-ijms-21-02548]\]. In addition, USP17 deubiquitinates the transcription factor ELK-1. The stabilization of ELK-1 increases the expression of cyclin D1 \[[@B32-ijms-21-02548]\]. USP17 further decreases Su(var)3-9, enhancer-of-zeste, and trithorax domain-containing protein 8 ubiquitination to trigger cellular senescence \[[@B33-ijms-21-02548]\].

For the G1/S phase, USP20 deubiquitinates and stabilizes the DNA checkpoint protein claspin, and thus activates the ATR-Chk1 signaling in the DNA damage response pathway \[[@B98-ijms-21-02548]\]. USP10 deubiquitinates SKP2 and augments the activation of Bcr-Abl by mediating deubiquitination and stabilization of SKP2 in chronic myelogenous leukemia cells \[[@B29-ijms-21-02548]\]. An RNAi-based screening study discovered that USP21 binds and deubiquitinates FOXM1, leading to its increased stability, which induces cell cycle progression in basal-like breast cancer \[[@B34-ijms-21-02548]\]. In addition, DUBs could regulate transcription factors for cell cycle control. The transcription factor Krüppel-like factor 5 (KLF5), which promotes cell proliferation by inhibiting the expression of the cell cycle inhibitor p27 \[[@B22-ijms-21-02548]\], is highly expressed in breast cancer. A genome-wide siRNA library screen identified BAP1 and USP3 as KLF5 DUBs. Both BAP1 and USP3 bind to and stabilize KLF5 via deubiquitination \[[@B22-ijms-21-02548],[@B35-ijms-21-02548]\], indicating the possible regulatory role of DUBs in cancer proliferation. Another example is the androgen receptor (AR), a key transcription factor in the development of breast cancer \[[@B99-ijms-21-02548]\]. It has been reported that AR can be stabilized by USP14, and depletion of USP14 reduces cell proliferation by blocking the G0/G1--S phase transition in AR-responsive breast cancer cells \[[@B30-ijms-21-02548]\].

For the S/G2/M phase, OTUD7B, also called cezanne, is frequently overexpressed in different cancer types, such as breast and lung cancer \[[@B100-ijms-21-02548],[@B101-ijms-21-02548]\]. It is reported to be a cell cycle-dependent DUB because it deubiquitylates substrates of the mitotic cyclin anaphase-promoting complex/cyclosome (APC/C) and prevents their degradation during mitosis \[[@B25-ijms-21-02548]\]. The APC/C is a key regulator of cell cycle progression through the regulation of CDK activity \[[@B26-ijms-21-02548]\]. OTUD7B controls the cell cycle through HIF2α and E2F1 in response to oncogenic signaling \[[@B27-ijms-21-02548]\]. In addition, it removes UBQ from GβL in the mTOR complex to regulate mTORC2 signaling in response to growth signals \[[@B28-ijms-21-02548]\]. Besides, DUB3 can directly deubiquitinate cyclin A in NSCLC. The depletion of DUB3 decreases cyclin A levels, leading to cell cycle arrest at the G0/G1-S phase checkpoint in NSCLC cells \[[@B23-ijms-21-02548]\]. Lastly, it is known that histone demethylases can regulate the cell cycle through transcriptional regulation \[[@B102-ijms-21-02548]\]. The histone demethylase PHF8 is stabilized by USP7, leading to the upregulation of cyclin A2, which is critical for cell growth and proliferation in breast carcinomas \[[@B36-ijms-21-02548]\].

3. DUBs and Cell Proliferation {#sec3-ijms-21-02548}
==============================

In addition to their role in regulating the cell cycle, DUBs have been reported to regulate cell proliferation through different cell signaling pathways, such as Wnt/β-catenin signaling, p53-mouse double minute 2 (MDM2) signaling, PI3K-Akt signaling, AR signaling, and transforming growth factor beta (TGF-β) signaling. Aberrant canonical Wnt/β-catenin signaling is tightly associated with many solid and liquid tumors \[[@B103-ijms-21-02548]\]. Furthermore, alteration or loss of differentiation control could facilitate the development of metastatic traits during tumorigenesis \[[@B104-ijms-21-02548],[@B105-ijms-21-02548]\]. Numerous studies have demonstrated the control of Wnt/β-catenin signaling by DUBs in cancer \[[@B48-ijms-21-02548],[@B106-ijms-21-02548]\]. USP6NL is elevated in colorectal cancer (CRC) and regulates β-catenin accumulation. Knockdown of USP6NL results in inhibition of cell proliferation and G0/G1 cell cycle arrest in human CRC cell lines \[[@B53-ijms-21-02548]\]. In addition, USP4 is a candidate for a β-catenin-specific DUB. There is a positive correlation between the levels of USP4 and β-catenin in human colon cancer tissues. Further, knockdown of USP4 reduces invasiveness and migration in colon cancer cells \[[@B48-ijms-21-02548]\]. β-catenin is also stabilized by USP9X, leading to high-grade glioma cell growth. USP9X removes the Lys48-linked polyubiquitin chains from β-catenin to prevent its proteasomal degradation. Depletion of USP9X induces G1-S cell cycle arrest and inhibits cell proliferation in glioblastoma cells \[[@B59-ijms-21-02548]\].

The tumor suppressor p53 is a transcription factor able to control important cellular pathways. It prevents genome mutation and plays protective roles in tumor onset and progression. It is mainly regulated by ubiquitylation, indicating the importance of DUBs in monitoring its ubiquitin cycle \[[@B107-ijms-21-02548]\]. Both MDM2 and p53 are targeted by different DUBs ([Figure 2](#ijms-21-02548-f002){ref-type="fig"}). Suppression of USP2 leads to MDM2 destabilization and results in p53 activation \[[@B44-ijms-21-02548]\]. USP7 plays a key role in the p53 pathway by stabilizing both MDM2 and p53 ([Figure 2](#ijms-21-02548-f002){ref-type="fig"}) \[[@B54-ijms-21-02548],[@B55-ijms-21-02548],[@B56-ijms-21-02548],[@B57-ijms-21-02548],[@B58-ijms-21-02548]\]. Under normal conditions, USP7 has a higher binding affinity to MDM2, the major E3 ligase of p53 \[[@B56-ijms-21-02548]\], and thus deubiquitylates MDM2 more efficiently to prevent its self-degradation and maintain stable protein levels for controlling p53 via the UBQ-proteasome pathway \[[@B108-ijms-21-02548]\]. USP10 regulates p53 localization and stability by deubiquitinating p53. It reverses MDM2-induced p53 nuclear export and degradation \[[@B40-ijms-21-02548]\]. Moreover, USP29 is reported to cleave poly-ubiqutin chains from p53 and thus stabilize it \[[@B47-ijms-21-02548]\], while USP15 stabilizes the E3 UBQ ligase MDM2 in cancer cells and regulates p53 function and cancer cell survival. Inhibition of USP15 induces apoptosis and boosts antitumor T cell responses in tumor cells \[[@B42-ijms-21-02548]\]. Furthermore, a large number of DUBs have been found to target p53 or p53-associated proteins directly, leading to proliferation. USP5 regulates p53 levels and alters cell growth and cell cycle distribution associated with p21 induction in melanoma cells \[[@B52-ijms-21-02548]\]. OTUD1 is required for p53 stabilization, and OTUD1 overexpression increases the cleavage of caspase-3 and PARP and subsequently increases apoptosis \[[@B38-ijms-21-02548]\]. Another p53-associated DUB, otubain 1 (OTUB1), is expressed in high-grade tumor types, such as lung, breast, and ovarian tumors. OTUB1 regulates p53 to promote tumor cell survival and proliferation \[[@B37-ijms-21-02548]\]. USP42 controls the level of p53 ubiquitination during the early phase of the DDR to promote DNA repair, resulting in the activation of p53-dependent transcription and cell-cycle arrest in response to stress \[[@B45-ijms-21-02548]\]. In addition, USP28 depletion leads to increased ubiquitinated H2A-K119 and decreased expression of p53, p21, and p16INK4a, suggesting a role for USP28 in cell proliferation via the control of p53 and p53-associated proteins \[[@B109-ijms-21-02548]\]. Additionally, USP28 deubiquitinates TP53-binding protein 1 to promote p53-mediated transcription \[[@B46-ijms-21-02548]\]. USP4 is a potential oncogene that inhibits p53 and NF-κB via histone deacetylases 2 (HDAC2) \[[@B49-ijms-21-02548],[@B50-ijms-21-02548]\]. USP9X-dependent p53 degradation was observed in hepatocellular carcinoma (HCC) cells treated with the small molecule DUB inhibitor WP1130 \[[@B60-ijms-21-02548]\].

DUBs are also involved in other signaling pathways that promote tumor proliferation. USP15, which stabilizes the type I TGF-β receptor and enhances the TGF-β pathway, is upregulated in various cancers \[[@B43-ijms-21-02548]\]. In addition, OTUD1 mitigates TGF-β-induced pro-oncogenic responses via deubiquitination of SMAD7 at lysine 220 in breast cancer \[[@B39-ijms-21-02548]\]. USP49 regulates the Akt pathway through the stabilization of FKBP51. FKBP51 activates PH domain leucine-rich-repeats protein phosphatase (PHLPP) to dephosphorylate Akt, which inhibits pancreatic cancer cell proliferation \[[@B51-ijms-21-02548]\]. The AR pathway is commonly activated in prostate cancer (PCa), and it plays a critical role in PCa growth and progression. USP14 was reported to bind with and stabilize AR in androgen-responsive PCa cells. Overexpression of USP14 promotes the proliferation of LNCaP cells \[[@B41-ijms-21-02548]\]. Furthermore, DUBs control different growth factors in tumor cells. For instance, USP8 prevents degradation of the epidermal growth factor receptor and thus promotes proliferation \[[@B110-ijms-21-02548]\].

4. DUBs and Apoptosis {#sec4-ijms-21-02548}
=====================

The ability to evade apoptosis is one of the essential changes in cancer cells that causes malignant transformation \[[@B111-ijms-21-02548]\]. Apoptosis is a cellular self-destruction program in response to various cellular stresses. The two extrinsic and intrinsic pathways in apoptosis both involve the activation of caspase molecules. The activation of initiator caspase will further lead to the activation of executioner caspase in apoptosis \[[@B112-ijms-21-02548]\]. DUBs were found to target different pro- and anti-apoptotic proteins in both the extrinsic and intrinsic pathways. ATXN3 stabilizes p53 by deubiquitination and promotes p53-mediated apoptosis \[[@B61-ijms-21-02548]\]. USP5 targets p53-unanchored UBQ polymers and regulates p53-mediated transcription. Depletion of USP5 controls tumor necrosis factor alpha apoptosis-inducing ligand (TRAIL)-mediated apoptotic responsiveness in TRAIL-resistant tumor cells, and this function of USP5 ubiquitination can be blocked by caspase 8-specific inhibitors \[[@B63-ijms-21-02548]\]. In addition, USP5 deubiquitinates the MAF bZIP transcription factor and prevents its degradation. Knockdown of USP5 leads to apoptosis in multiple myeloma cells \[[@B64-ijms-21-02548]\]. In a chemoresistant xenograft model, JOSD1 was identified to be upregulated during the development of chemoresistance. Moreover, JOSD1 has been reported to deubiquitinate and stabilize MCL1, which plays a suppressive role in mitochondrial apoptotic signaling. Therefore, depletion of JOSD1 leads to severe apoptosis in gynecological cancer cells through the degradation of MCL1 \[[@B62-ijms-21-02548]\]. There are several DUBs that regulate the apoptotic pathways via BCL-2 family, an inhibitor of apoptotic proteins (IAPs) and caspases. DUB3/USP17 induces apoptosis through caspase 3 activation \[[@B113-ijms-21-02548]\], whereas USP15 plays a role in stabilizing procaspse 3 \[[@B114-ijms-21-02548]\]. Besides, A20, a DUB belongs to the OTU subclass, interacts with caspase 8 to reverse the ubiquitination of a cullin 3-based E3 ligase \[[@B115-ijms-21-02548]\]. As for the IAPs, they are a class of proteins that inhibit apoptosis. They contain the baculovirus IAP repeat domain and the RING domain that provides the E3 ligase property \[[@B116-ijms-21-02548]\]. USP19 stabilizes the cellular IAP1 and cellular IAP2 during caspase activation and apoptosis \[[@B117-ijms-21-02548]\]; OTUD1 was found to regulate the TNF-dependent cell death by modulating the cellular IAP1 stability \[[@B118-ijms-21-02548]\]. Furthermore, USP9X was reported to interact with an E3 ligase X-linked IAP for mitotic cell fate decision \[[@B119-ijms-21-02548]\]. In addition, USP27X was found to interact with the BIM. BIM is a pro-apoptotic BH3-only protein that regulates the cell death proteins such as BAX. Overexpression of Usp27x reduces BIM ubiquitination, and induces apoptosis in tumor cells. On the other hand, suppression of USP27X could reduce apoptosis \[[@B120-ijms-21-02548]\].

5. DUBs and the DDR {#sec5-ijms-21-02548}
===================

Cells undergo DDR to sense and repair unique lesion structures in the damaged DNA. Efficient DDR protects cells from genomic instability \[[@B121-ijms-21-02548],[@B122-ijms-21-02548]\]. Ubiquitination regulates DDR by controlling DDR protein localization, activity, and stability \[[@B123-ijms-21-02548]\]. DUBs play critical roles in different stages of the DDR through the regulation of many molecules involved in DNA repair ([Figure 3](#ijms-21-02548-f003){ref-type="fig"}). DNA repair is important for preventing tumor formation \[[@B124-ijms-21-02548]\]. Proliferating cell nuclear antigen (PCNA) is a key molecule that mediates the tolerance to DNA damage and allows the growth of tumors. PCNA is monoubiquitinated in response to DNA damage. A fission yeast study showed the importance of UBP2, UBP12, and UBP15 in the stabilization of mono, di, and polyubiquitylated forms of PCNA, which sensitize cells to DNA damage \[[@B69-ijms-21-02548]\]. In addition, PCNA can be deubiquitinated by USP1 in the crosslink repair pathway in Fanconi anemia \[[@B71-ijms-21-02548],[@B72-ijms-21-02548],[@B73-ijms-21-02548]\]. In a complex with its cofactor UAF1, USP1 reverses PCNA ubiquitination \[[@B74-ijms-21-02548]\]. UCHL5 regulates double-strand break (DSB) resection and repair by homologous recombination through protecting its interactor, NFRKB, from degradation \[[@B70-ijms-21-02548]\]. In addition, USP20 plays role in genome maintenance and DNA repair by enhancing recombinational repair of collapsed replication forks \[[@B125-ijms-21-02548]\]. Furthermore, USP9X regulates the DNA checkpoint protein claspin during S phase, suggesting a role in DNA repair \[[@B79-ijms-21-02548]\]. USP7-promoted PHF8 stabilization confers cellular resistance to genotoxic insults and is required for the recruitment of BLM and KU70, which are both essential for DNA DSB repair \[[@B36-ijms-21-02548]\].

Breast-cancer susceptibility gene (BRCA) 1 contributes to DNA repair and the maintenance of chromosomal stability in response to DNA damage \[[@B126-ijms-21-02548]\]. BRCA1 appears to play roles in two distinct pathways of DSB repair, non-homologous end joining and homology-directed repair, through the regulation of different effectors. It has been reported that several DUBs can regulate BRCA1. The BRCA1-associated DUB BAP1 is mutated in mesothelioma and melanoma \[[@B65-ijms-21-02548]\]. BAP1 is a phosphorylation target for the DDR kinase ATM, and BAP1 mediates rapid poly(ADP-ribose)-dependent recruitment of the polycomb DUB complex PR-DUB to repair DNA DSBs \[[@B65-ijms-21-02548]\]. In addition, both cezanne (OTUD7B) and cezanne2 (OTUD7A) promote the recruitment of the Rap80/BRCA1-A complex by binding to Lys63-polyubiquitin and targeting Lys11-polyubiquitin in response to DNA repair \[[@B68-ijms-21-02548]\]. Another DUB, USP11, forms a complex with BRCA2. It deubiquitylates the partner and localizer of BRCA2 to enhance DNA repair \[[@B75-ijms-21-02548]\]. BRCA1/BRCA2-containing complex 3 (BRCC3) is a Lys63-specific DUB involved in the DDR. BRCC3 inactivation increases the release of several cytokines, including G-CSF, which enhances proliferation in AML cell lines \[[@B127-ijms-21-02548]\]. Further, OTUD5, a specific stabilizer of the UBR5 E3 ligase, is reported to localize at DNA DSBs. OTUD5 plays two roles at DSBs. First, OTUD5 interacts with UBR5 and represses RNA Pol II-mediated elongation and RNA synthesis. In addition, OTUD5 interacts with the FACT component SPT16 and antagonizes histone H2A deposition at DSBs \[[@B67-ijms-21-02548]\].

Histone ubiquitination at DNA breaks is required for activation of the DDR and DNA repair. BRCA1-BARD1-catalyzed ubiquitination of histone H2A primes chromatin for repair by homologous recombination during the DDR. Ubiquitination of histone H2A and γH2AX by the UBQ ligases RNF168 and RNF8 generates a cascade of ubiquitination. USP3 deubiquitinates ubiquitinated γH2AX and H2A \[[@B76-ijms-21-02548]\]. USP48 is another H2A DUB that is specific for the C-terminal BRCA1 ubiquitination site. USP48 promotes genomic stability by antagonizing the BRCA1 E3 ligase function. Depletion of USP48 increases the distance between p53-binding protein 1 (53BP1) from the DNA break point \[[@B77-ijms-21-02548]\]. It should be noted that histone ubiquitination by RNF168 is a critical event for the recruitment of BRCA1 and 53BP1, and the stability of RNF168 can be regulated by USP7. Depletion of USP7 impairs H2A and γH2AX monoubiquitination, leading to decreases in the levels of pBmi1, Bmi1, RNF168, and BRCA1 under ultraviolet radiation-induced DNA damage \[[@B78-ijms-21-02548]\]. Moreover, USP3, a histone H2A DUB, negatively regulates UBQ-dependent DDR signaling through regulation of chromatin ubiquitination in response to genotoxic stress \[[@B128-ijms-21-02548]\]. Lastly, CYLD deubiquitinates p53 and facilitates its stabilization in response to genotoxic stress. Loss of CYLD catalytic activity causes impaired DNA damage-induced p53 stabilization and activation of skin tumorigenesis \[[@B66-ijms-21-02548]\].

6. DUBs and Tumor Suppressors/Oncogenes {#sec6-ijms-21-02548}
=======================================

DUBs play an important role in cancer development by controlling various different tumor suppressors and oncogenes. CYLD was first identified as the tumor suppressor gene for cylindromatosis \[[@B129-ijms-21-02548]\]. Its protein expression level is downregulated in various tumor types \[[@B130-ijms-21-02548],[@B131-ijms-21-02548]\]. CYLD plays an essential role in NF-κB \[[@B82-ijms-21-02548]\] and c-Jun N-terminal kinase pathways \[[@B132-ijms-21-02548]\]. Briefly, it inhibits NF-κB activation by promoting deubiquitylation of several UBQ-dependent NF-κB positive regulators, such as tumor necrosis factor receptor-associated factor 2 and the NF-κB essential modulator/IKKγ subunit \[[@B80-ijms-21-02548],[@B81-ijms-21-02548],[@B82-ijms-21-02548]\]. Enhanced and/or prolonged NF-κB signaling due to reduced CYLD activity increases cellular apoptosis resistance and the chances of tumor formation \[[@B133-ijms-21-02548]\]. USP13 also acts as a tumor suppressor through its regulation of the phosphatase and tensin homolog deleted on chromosome 10 (PTEN)/AKT pathway in oral squamous cell carcinoma. Overexpression of USP13 induces PTEN expression and represses the activation of AKT, glucose transporter-1, and hexokinase-2, leading to growth inhibition \[[@B84-ijms-21-02548]\]. In an RNAi screen, USP11 was identified as a promyelocytic leukemia (PML) regulator to deubiquitinate and stabilize PML, counteracting the functions of PML. UBQ ligases RNF4 and the KLHL20-Cullin 3-Roc1 complex \[[@B83-ijms-21-02548]\]. This complex causes suppression of PML in many cancer types \[[@B83-ijms-21-02548]\]. PHLPP is a family of Ser/Thr protein phosphatases that serve as tumor suppressors by negatively regulating AKT. In CRC, USP46 is reported to bind to PHLPP and directly remove its polyubiquitin chains, resulting in the stabilization of PHLPP. USP46-mediated stabilization of PHLPP subsequently inhibits AKT, blocking proliferation and tumorigenesis in colon cancer cells \[[@B85-ijms-21-02548]\].

A large number of DUBs have been reported to bind with and stabilize oncogenes, such as c-MYC. USP22 promotes deubiquitination of c-MYC in breast cancer cells, resulting in increased levels of c-MYC. Overexpression of USP22 stimulates tumorigenic activity in breast cancer cells and is closely correlated with breast cancer progression \[[@B87-ijms-21-02548]\]. USP9X acts as an FBW7 interactor, and the loss of FBW7 has been observed in many types of human cancer \[[@B134-ijms-21-02548]\]. USP9X antagonizes FBW7-mediated ubiquitylation and causes FBW7 stabilization. USP9X suppresses tumor formation by regulating FBW7 protein stability, which reduces c-MYC levels \[[@B89-ijms-21-02548]\]. The degradation of the oncogene product MYC is also enhanced by USP28 \[[@B88-ijms-21-02548]\]. An integrated genomic analysis of malignant pleural mesotheliomas uncovered somatic inactivating mutations in the tumor-suppressive nuclear DUB BAP1. BAP1 targets histones with the polycomb repressor subunit ASXL1 \[[@B86-ijms-21-02548]\].

7. DUBs and Metastasis {#sec7-ijms-21-02548}
======================

Metastasis, which is the ability of cancer cells spread to different tissues or organs, is regulated by many mechanisms. It is a series of biological processes including various invasion-metastasis cascades. Multiple reports have suggested the role of DUBs in controlling these mechanisms. The epithelial--mesenchymal transition (EMT) represents one of the most important invasive events in cancer metastasis. It refers to a change of a subset of adhesion molecules in cells: adopting a migratory and invasive behavior \[[@B135-ijms-21-02548]\]. Numerous DUBs are involved in cancer cell invasiveness through the regulation of different EMT transcription factors ([Figure 4](#ijms-21-02548-f004){ref-type="fig"}).

SNAIL is a key regulator of EMT and plays an important role in tumor progression and metastasis. A group of DUBs, including OTUB1, DUB3, and USP3, are reported to stabilize Snail through preventing its ubiquitination and proteasomal degradation. OTUB1 promotes metastasis of esophageal squamous cell carcinoma through the stabilization of Snail \[[@B92-ijms-21-02548]\]. DUB3 is found to be overexpressed in breast cancer, and depletion of DUB3 leads to Snail1 destabilization, which suppresses EMT, tumor invasiveness, and metastasis \[[@B90-ijms-21-02548]\]. In addition, DUB3 also interacts with SLUG and TWIST and prevents their degradation, thereby promoting migration, invasion, and cancer stem cell-like properties in breast cancer cells \[[@B91-ijms-21-02548]\]. Moreover, USP3 is significantly upregulated in glioblastomas and gastric cancer (GC). Clinicopathological data demonstrate that USP3 correlates with a shorter overall and relapse-free survival in glioblastomas \[[@B136-ijms-21-02548]\]. It has also been reported that USP3 interacts with and stabilizes SUZ12 via deubiquitination. Expression of SUZ12 is negatively correlated with E-cadherin, which promotes migration and EMT in GC cells \[[@B95-ijms-21-02548]\]. SMAD4 has been found to regulate EMT. USP17 is upregulated in osteosarcoma tissues and stabilizes SMAD4 through its DUB activity, leading to enhanced osteosarcoma cell invasion \[[@B94-ijms-21-02548]\].

In addition to EMT mediators, DUBs target other molecules involved in cancer invasiveness. High expression of 14-3-3γ is found in various cancers, such as breast cancer and NSCLC \[[@B137-ijms-21-02548],[@B138-ijms-21-02548]\]. Overexpression of 14-3-3γ promotes cell migration and invasion and correlates with the invasiveness of cancer cells. USP37 regulates the stability of 14-3-3γ through its DUB activity \[[@B97-ijms-21-02548]\]. Another DUB, 26S proteasome non-ATPase regulatory subunit 14 (PSMD14), is a posttranslational regulator of growth factor receptor bound protein 2 (GRB2). PSMD14 is significantly upregulated in HCC tissues, and it inhibits the degradation of GRB2 via deubiquitination. Overexpression of PSMD14 correlates with vascular invasion, tumor recurrence, and poor tumor-free and overall survival in patients with HCC \[[@B93-ijms-21-02548]\]. The small GTPase Ras-related protein RAB7 is an early-induced melanoma driver and endocytosis protein that favors tumor invasion \[[@B139-ijms-21-02548]\]. It is suggested to play roles in modulating endosomal maturation and autophagosome resolution in various cell types \[[@B140-ijms-21-02548],[@B141-ijms-21-02548]\]. It was recently shown to be regulated by USP32 \[[@B96-ijms-21-02548]\].

8. DUBs as Therapeutic Targets for Cancer Treatment {#sec8-ijms-21-02548}
===================================================

As mentioned above, DUBs have been shown to deubiquitinate many targets involved in different characteristics of cancer ([Table 2](#ijms-21-02548-t002){ref-type="table"}), suggesting that DUBs may be potential therapeutic targets in cancer treatment. Indeed, many studies have been conducted to examine the potential of DUBs in cancer therapeutics. As DUBs are part of the proteasome system, proteasome inhibitors target them, which has shown promising successes for cancer treatment. Several examples are given below. Bortezomib, the first proteasome inhibitor, has entered clinical practice to treat relapsed multiple myeloma and showed outstanding antimyeloma activity \[[@B142-ijms-21-02548],[@B143-ijms-21-02548]\]. In addition, combination of bortezomib and epirubicin significantly increases the sensitivity of colorectal carcinoma cells to apoptosis \[[@B144-ijms-21-02548]\]. Due to the resistance to bortezomib, next-generation proteasome inhibitors carfilzomib and ixazomib have been approved. Carfilzomib irreversibly binds to the β-5 subunit of the proteasome \[[@B145-ijms-21-02548]\]. A preclinical study has demonstrated that carfilzomib increased efficacy against bortezomib-resistant multiple myeloma \[[@B146-ijms-21-02548]\]. In the Phase 2 and Phase 3 clinical trials, single-agent carfilzomib provided durable anticancer activity in patients with relapsed and/or refractory multiple myeloma \[[@B147-ijms-21-02548]\]. Ixazomib, the first oral proteasome inhibitor to enter the clinic, is now commonly used for multiple myeloma treatment. It is an efficacious and long-term therapy for patients with advanced stage multiple myeloma \[[@B148-ijms-21-02548]\]. In a double-blind Phase 3 trial, the use of ixazomib significantly improved progression-free survival in patients with relapsed and/or refractory multiple myeloma \[[@B149-ijms-21-02548]\].

In addition to proteasome inhibitors, numerous DUB therapeutic targets have been developed. One excellent and classical example is USP7. Activating p53 by inhibiting MDM2 is a major direction of cancer treatment \[[@B150-ijms-21-02548],[@B151-ijms-21-02548]\]. Nutlin-3 from Roche and RITA (2,5-bis(5-hydroxymethyl-2-thienyl)furan (NSC652287)) from the National Cancer Institute have been developed for interfering with the MDM2/p53 interaction to induce p53 and therefore cell death in human tumor cells \[[@B152-ijms-21-02548],[@B153-ijms-21-02548],[@B154-ijms-21-02548]\]. They represent an important class of small molecules that has significant antitumor effects without obvious toxicity in mice \[[@B153-ijms-21-02548],[@B155-ijms-21-02548]\], which further suggests that promoting MDM2 degradation will provide a therapeutic benefit when treating p53-related cancers. Additionally, USP7 silencing promotes the degradation of MDM2 and thus abrogates p53 degradation. Targeting DUBs might provide a new direction for cancer treatment, as it has the advantage of a simpler mechanism than targeting UBQ ligases or the 26S proteasome \[[@B150-ijms-21-02548],[@B156-ijms-21-02548]\]. A small molecule lead-like inhibitor of USP7, HBX41108, which stabilizes and activates p53, was identified using high-throughput screening \[[@B156-ijms-21-02548]\]. This inhibitor symbolizes a milestone in DUB drug development and sheds light on new potential cancer therapies using DUB inhibitors.

In addition, many cancer studies have focused on the apoptotic role of DUBs and exploited this role for chemotherapy. A drug screening study demonstrated that the small molecule DUB inhibitor b-AP15 inhibits two DUBs, USP14 and UCHL5. Treatment with b-AP15 results in apoptosis of human Waldenström macroglobulinemia (WM) cell lines and primary WM tumor cells \[[@B157-ijms-21-02548]\]. In another chemotherapeutic study, pharmacological targeting of USP14 with the FDA-approved small-molecule inhibitor VLX1570 decreased viability in endometrial cancer cells through cell cycle arrest and caspase 3-mediated apoptosis \[[@B158-ijms-21-02548]\]. The oncogenic transcription factor pre-B cell leukemia homeobox-1 (PBX1) promotes advanced PCa cell proliferation. USP9X interacts with and stabilizes the PBX1 protein by attenuating its Lys48-linked polyubiquitination. The USP9X inhibitor WP1130 markedly induces PBX1 degradation and promotes PCa cell apoptosis \[[@B159-ijms-21-02548]\]. The selected DUB inhibitors that target on cancer cells are summarized in [Table 3](#ijms-21-02548-t003){ref-type="table"}. To conclude, DUBs play multiple roles in cellular functions. The aberrant expression and regulation of these enzymes have been shown to contribute to promote tumorigenesis, making them promising therapeutic targets for cancer therapy.
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p53-binding protein 1
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protein kinase B

APC/C

anaphase-promoting complex/cyclosome

AR

androgen receptor

BAP1

BRCA1 associated protein 1

BRCA

breast-cancer susceptibility gene

BRCC3

BRCA1/BRCA2-containing complex 3

CDK

cyclin-dependent kinase

CRC

colorectal cancer

DDR

DNA damage response

DSB

double-strand break

DUB

Deubiquitinase

ELK-1

ETS like-1 protein

EMT

epithelial-mesenchymal transition

FBW7

F-box and WD repeat domain-containing 7

FKBP51

FK506-binding protein 51

GC

gastric cancer

GRB2

growth factor receptor bound protein 2

HCC

hepatocellular carcinoma

JOSD1

Josephin domain containing 1

KLF5

Krüppel-like factor 5

MDM2

mouse double minute 2

mTORC1

mammalian target of rapamycin complex 1

NK-κB

nuclear factor kappa-light-chain-enhancer of activated B cells

NSCLC

non-small cell lung cancer

OTUB1

otubain 1

OTU

otubain protease

PBX1

pre-B cell leukemia homeobox-1

PCa

prostate cancer

PCNA

proliferating-cell nuclear antigen

PHF8

PHD finger protein 8

PHLPP

PH domain leucine-rich-repeats protein phosphatase

PML

promyelocytic leukemia

PSMD14

26S proteasome non-ATPase regulatory subunit 14

PTEN

phosphatase and tensin homolog deleted on chromosome 10

RNF

ring finger proteins

SKP2

S-phase kinase associated protein 2.

TGF-β

transforming growth factor beta

TRAIL

tumor necrosis factor alpha apoptosis-inducing ligand

UBQ

ubiquitin

UBR5

ubiquitin protein ligase E3 component N-recognin 5

UCH

ubiquitin C-terminal hydrolases

UCHL

ubiquitin C-terminal hydrolases like

USP

ubiquitin-specific protease

WM

Waldenström macroglobulinemia

![Roles of DUBs in cell cycle control in cancers. The eukaryotic cell cycle consists of the G1 phase (blue), the S-phase (brown), the G2 phase (yellow), and the M (mitosis) phase (green). Cells can enter a quiescent state, the G0 phase (grey). Cell cycle phases are indicated by different colored arrows. The cell cycle is regulated by complexes that are composed of cyclins (light purple), and its relative cyclin-dependent protein kinases (CDKs) (pink). The cyclin-CDK complex plays regulatory roles in the cell cycle. The red arrows indicate their targets, either within the designated cell cycle phase or in the transition state. Various DUBs have been shown to interact with the cyclin--cdk complex. DUBs that participate in G1 phase are labeled in light blue; S phase in light brown; G2 phase in light yellow; and M phase in light green. The detailed interaction partner of each individual DUB can be found in the main text and the [Table 2](#ijms-21-02548-t002){ref-type="table"}.](ijms-21-02548-g001){#ijms-21-02548-f001}

![DUBs in MDM2-p53 pathways. Ubiquitination is found on both p53 and MDM2 molecules; various DUBs could revise that via deubiquitination to regulate the p53 pathway. DUBs' targets on p53 are labeled in light brown; those that interact with MDM2 are labeled in light yellow. Detailed descriptions can be referred to the main text.](ijms-21-02548-g002){#ijms-21-02548-f002}

![Roles of DUBs in DNA damage response. Various DUBs (light purple) have been shown to interact with molecules (various colors) that play roles in DNA repair and chromosomal stability during DNA damage. Proliferating cell nuclear antigen (PCNA) plays important roles during DNA replication and repair, while BRCA members are the key players in repairing the DNA lesions such as DNA double-strand breaks. In addition, BLM repairs DNA double-strand breaks to maintain genome stability. Detailed information can be found in the main text.](ijms-21-02548-g003){#ijms-21-02548-f003}

![Roles of DUBs in epithelial--mesenchymal transition (EMT) in cancer metastasis. Epithelial cells are held together by numerous proteins, including tight junctions, adherens junctions, and desmosomes. These cells express molecules that are associated with the epithelial state, such as E-cadherin in epithelial state, and N-cadherin in mesenchymal state. Induction of EMT induces different EMT-inducing transcription factors (EMT-TFs) such as SNAIL, SLUG, and TWIST. These factors can then inhibit the epithelial state-related genes, such as E-cadherin, and activate the mesenchymal state related genes, such as N-cadherin. Various DUBs have been shown to interact with different EMT regulators. EMT is a reversible process, and mesenchymal cells can revert to the epithelial state by undergoing mesenchymal--epithelial transition (MET). A detailed description can be found in the main text.](ijms-21-02548-g004){#ijms-21-02548-f004}
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###### 

The sub-cellular localizations of DUBs in mammalian cells.

  Organelle                                DUBs
  ---------------------------------------- -----------------------------------------------------------------------------------------------------------
  Nucleolus                                USP36, USP39
  Nucleus                                  BAP1, MYSM1, USP1, USP11, USP22, USP26, USP28, USP29, USP3, USP42, USP44, USP49, USP51, USP7, USPL1, ZUP1
  Golgi                                    USP32, USP33
  Endoplasmic reticulum                    ATXN3, USP13, USP19, USP33, YOD1
  Microtubules                             CYLD, USP21
  Centriole                                USP21, USP33, USP9X
  Early endosome and multivesicular body   AMSH, AMSH-LP, USP2a, USP8
  Lipid droplet                            USP35
  Peroxisome and mitochondrion             USP30
  Cajal body                               USPL1
  Stress granule                           USP10, USP13, USP5
  Plasma membrane                          JOSD1, USP6
  Cytoplasm                                A20, CYLD, PSMD14, UCHL5, USP14
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###### 

Functional roles of DUBs in cancer properties.

  Functions            DUBs       Targets                                                                                References
  -------------------- ---------- -------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------
  Cell cycle control   BAP1       KLF5                                                                                   \[[@B22-ijms-21-02548]\]
                       DUB3       cyclin A                                                                               \[[@B23-ijms-21-02548]\]
                       OTUD6B-2   cyclin D1 and c-Myc                                                                    \[[@B24-ijms-21-02548]\]
                       OTUD7B     APC/C, GβL, HIF2α and E2F1                                                             \[[@B25-ijms-21-02548],[@B26-ijms-21-02548],[@B27-ijms-21-02548],[@B28-ijms-21-02548]\]
                       USP10      SKP2, Bcr-Abl                                                                          \[[@B29-ijms-21-02548]\]
                       USP14      AR                                                                                     \[[@B30-ijms-21-02548]\]
                       USP17      p21, ELK-1, Su(var)3-9, Enhancer-of-zeste, and Trithorax domain-containing protein 8   \[[@B31-ijms-21-02548],[@B32-ijms-21-02548],[@B33-ijms-21-02548]\]
                       USP21      FOXM1                                                                                  \[[@B34-ijms-21-02548]\]
                       USP3       KLF5                                                                                   \[[@B35-ijms-21-02548]\]
                       USP7       PHF8                                                                                   \[[@B36-ijms-21-02548]\]
  Cell proliferation   OTUB1      p53                                                                                    \[[@B37-ijms-21-02548]\]
                       OTUD1      p53, SMAD7                                                                             \[[@B38-ijms-21-02548],[@B39-ijms-21-02548]\]
                       USP10      p53                                                                                    \[[@B40-ijms-21-02548]\]
                       USP14      AR                                                                                     \[[@B41-ijms-21-02548]\]
                       USP15      MDM2, TGF-β receptor                                                                   \[[@B42-ijms-21-02548],[@B43-ijms-21-02548]\]
                       USP2       MDM2                                                                                   \[[@B44-ijms-21-02548]\]
                       USP28      p53, p21, and p16INK4a                                                                 \[[@B45-ijms-21-02548],[@B46-ijms-21-02548]\]
                       USP29      p53                                                                                    \[[@B47-ijms-21-02548]\]
                       USP4       β-catenin, p53 and NF-κB                                                               \[[@B48-ijms-21-02548],[@B49-ijms-21-02548],[@B50-ijms-21-02548]\]
                       USP42      P53                                                                                    \[[@B45-ijms-21-02548]\]
                       USP49      FKBP51                                                                                 \[[@B51-ijms-21-02548]\]
                       USP5       P53                                                                                    \[[@B52-ijms-21-02548]\]
                       USP6NL     β-catenin                                                                              \[[@B53-ijms-21-02548]\]
                       USP7       MDM2                                                                                   \[[@B54-ijms-21-02548],[@B55-ijms-21-02548],[@B56-ijms-21-02548],[@B57-ijms-21-02548],[@B58-ijms-21-02548]\]
                       USP9X      β-catenin, p53                                                                         \[[@B59-ijms-21-02548],[@B60-ijms-21-02548]\]
  Cell apoptosis       ATXN3      p53                                                                                    \[[@B61-ijms-21-02548]\]
                       JOSD1      MCL1                                                                                   \[[@B62-ijms-21-02548]\]
                       USP5       p53, MAF bZIP                                                                          \[[@B63-ijms-21-02548],[@B64-ijms-21-02548]\]
  DNA damage repair    BAP1       PR-DUB                                                                                 \[[@B65-ijms-21-02548]\]
                       CYLD       p53                                                                                    \[[@B66-ijms-21-02548]\]
                       OTUD5      SPT16                                                                                  \[[@B67-ijms-21-02548]\]
                       OTUD7A     Rap80/BRCA1-A complex                                                                  \[[@B68-ijms-21-02548]\]
                       OTUD7B     Rap80/BRCA1-A complex                                                                  \[[@B68-ijms-21-02548]\]
                       UBP12      PCNA                                                                                   \[[@B69-ijms-21-02548]\]
                       UBP2       PCNA                                                                                   \[[@B69-ijms-21-02548]\]
                       UCHL5      NFRKB                                                                                  \[[@B70-ijms-21-02548]\]
                       USP1       PCNA                                                                                   \[[@B71-ijms-21-02548],[@B72-ijms-21-02548],[@B73-ijms-21-02548],[@B74-ijms-21-02548]\]
                       USP11      BRCA2                                                                                  \[[@B75-ijms-21-02548]\]
                       UBP15      PCNA                                                                                   \[[@B69-ijms-21-02548]\]
                       USP3       γH2AX and H2A                                                                          \[[@B76-ijms-21-02548]\]
                       USP48      BRCA1                                                                                  \[[@B77-ijms-21-02548]\]
                       USP7       PHF8, pBmi1, Bmi1, RNF168, and BRCA1                                                   \[[@B36-ijms-21-02548],[@B78-ijms-21-02548]\]
                       USP9X      claspin                                                                                \[[@B79-ijms-21-02548]\]
  Tumor suppression    CYLD       tumor necrosis factor receptor-associated factor 2, IKKγ                               \[[@B80-ijms-21-02548],[@B81-ijms-21-02548],[@B82-ijms-21-02548]\]
                       USP11      PML                                                                                    \[[@B83-ijms-21-02548]\]
                       USP13      PTEN                                                                                   \[[@B84-ijms-21-02548]\]
                       USP46      PHLPP                                                                                  \[[@B85-ijms-21-02548]\]
  Oncogene             BAP1       ASXL1                                                                                  \[[@B86-ijms-21-02548]\]
                       USP22      c-Myc                                                                                  \[[@B87-ijms-21-02548]\]
                       USP28      MYC                                                                                    \[[@B88-ijms-21-02548]\]
                       USP9X      FBW7                                                                                   \[[@B89-ijms-21-02548]\]
  Metastasis           DUB3       Snail, Slug and Twist                                                                  \[[@B90-ijms-21-02548],[@B91-ijms-21-02548]\]
                       OTUB1      Snail                                                                                  \[[@B92-ijms-21-02548]\]
                       PSMD14     GRB2                                                                                   \[[@B93-ijms-21-02548]\]
                       USP17      SMAD4                                                                                  \[[@B94-ijms-21-02548]\]
                       USP3       SUZ12                                                                                  \[[@B95-ijms-21-02548]\]
                       USP32      RAB7                                                                                   \[[@B96-ijms-21-02548]\]
                       USP37      14-3-3γ                                                                                \[[@B97-ijms-21-02548]\]
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###### 

Summary of known DUB inhibitors that are targeted in cancer cells.

  DUBs                    DUBs Inhibitors                                                 Therapeutic Targets                                 Functional Effects                                                                                                           References
  ----------------------- --------------------------------------------------------------- --------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------
  USP8                    9-Ethyloxyimino-9H-indeno\[1,2-b\]pyrazine-2,3-dicarbonitrile   Non-small cell lung cancer                          Downregulation of receptor tyrosine kinases including EGFR, ERBB2, ERBB3, and MET                                            \[[@B160-ijms-21-02548]\]
  UCHL1                   LDN-57444                                                       Lung cancer cell line                               Inhibit proliferation                                                                                                        \[[@B161-ijms-21-02548]\]
  UCHL1, UCHL3            TCID                                                            Multiple myeloma                                    Induce apoptosis                                                                                                             \[[@B162-ijms-21-02548]\]
  USP1                    Pimozide                                                        Leukemic cell lines                                 Promoted the degradation of ID1                                                                                              \[[@B163-ijms-21-02548]\]
  USP1-UAF1               ML323                                                           Non-small cell lung cancer and osteosarcoma cells   Induced DNA damage                                                                                                           \[[@B164-ijms-21-02548]\]
  USP1-UAF1               Pimozide and GW7647                                             Non--small cell lung cancer                         Inhibit cell proliferation                                                                                                   \[[@B165-ijms-21-02548]\]
  USP2                    ML346                                                           Colorectal cancer nad mantle cell lymphoma          Accelerate cyclin D1 degradation, cell cycle arrest                                                                          \[[@B166-ijms-21-02548]\]
  USP2a/USP2b/USP5/USP8   AM146, RA-9 and RA-14                                           Breast, ovarian and cervical cancer cell lines      Downregulation cell-cycle promoter, and upregulation of tumor suppressor                                                     \[[@B167-ijms-21-02548]\]
  USP5/IsoT, USP4         Vialinin A                                                      Basophilic leukemia cells                           Inhibit the release of TNFα                                                                                                  \[[@B168-ijms-21-02548]\]
  USP7                    HBX 41,108                                                      Colorectal carcinoma                                Induced p53-dependent apoptosis                                                                                              \[[@B156-ijms-21-02548]\]
  USP7/USP47              P5091 and Compound 1                                            Multiple myeloma                                    Induce apoptosis, inhibit tumor growth                                                                                       \[[@B169-ijms-21-02548],[@B170-ijms-21-02548]\]
  USP9X/USP5/USP24        WP1130                                                          Mantle cell lymphoma                                Downregulation of antiapoptotic and upregulation of proapoptotic proteins, such as MCL-1 and p53                             \[[@B171-ijms-21-02548],[@B172-ijms-21-02548]\]
  USP14/ UCHL5            AC17                                                            Human lung cancer cells                             Inhibit NFκB pathway and reactive p53                                                                                        \[[@B173-ijms-21-02548]\]
  USP14/UCHL5             b-AP15 (WO2013058691)                                           Multiple myeloma/ colorectal carcinoma              Downregulation of CDC25C, CDC2, and cyclin B1/ overexpression of the anti-apoptotic mediator Bcl-2 and anti-tumor activity   \[[@B162-ijms-21-02548],[@B174-ijms-21-02548]\]
  USP14/UCHL5             VLX1570                                                         Colon carcinoma cell                                Inhibit proteasome DUB activity                                                                                              \[[@B175-ijms-21-02548]\]
